Skip to content

mRNA HIV vaccine achieves 97 percent efficacy in George Washington School of Medicine and Health Sciences human trials

People in this story

George Washington Hatchet, January 2023

The George Washington School of Medicine and Health Sciences achieved a 97 percent success rate after conducting the first-ever human trials of the mRNA HIV vaccine over the past year, according to a release the school issued last month.

Researchers created a molecule inside the vaccine that elicits a response from bnAb precursor B cells, which eventually turn into cells that produce bnAbs – neutralizing antibodies that target the HIV virus, according to the study’s release. David Diemert, the clinical director of the GW Vaccine Research Unit, said in the release that the trials produced an efficacy rate that is more than 66 percent higher than any other HIV vaccine that has been tested on humans.

Continue reading at The George Washington Hatchet.

More Stories

There are two northern white rhinos left, both females. Here’s how science hopes to save them from extinction


A controversial technology is creating an unprecedented rift among climate scientists


Police cars are a form of PR — and the message is always the same

In the News